Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Active Psoriatic Arthritis Clinical Trial

Official title:
A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Status Recruiting

Clinical Trial Summary

This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04314544
Study type	Interventional
Source	Sun Pharmaceutical Industries Limited
Contact	Head, Clinical development
Phone	91 2266455645
Email	Clinical.Trial@sunpharma.com
Status	Recruiting
Phase	Phase 3
Start date	July 1, 2020
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03357471` - Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease	Phase 3
Active, not recruiting	`NCT04314531` - Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)	Phase 3
Withdrawn	`NCT05499416` - Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis	Phase 4
Recruiting	`NCT04876781` - Korean Post-marketing Surveillance for Xeljanz XR
Completed	`NCT02980692` - Efficacy and Safety Study of SUNPG1623	Phase 2
Completed	`NCT03881059` - Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)	Phase 2